文献速递肝病

HBV/HCV 合并感染对肝硬化及其后果的负面影响

The negative impact of HBV/HCV coinfection on cirrhosis and its consequences.
PubMed 文献 · Aliment Pharmacol Ther · 2017-10-09

在 ANRS CO22 HEPATHER 队列 20936 例患者中,95 例 HBV/HCV 合并感染者按年龄、性别及诊断时间与 375 例 HBV 单感染和 380 例 HCV 单感染患者匹配。合并感染者 F3-F4 纤维化(58%)较 HBV 单感染(32%)更常见,失代偿期肝硬化(11%)较 HBV 单感染(2%)和 HCV 单感染(4%)更常见。作者认为 HCV 合并感染加重 HBV 患者的肝纤维化,合并感染者失代偿期肝硬化增加,抗 HCV 治疗在合并感染与单感染中同样安全有效,应按 HCV 单感染相同规则考虑。

要点

  • 合并感染者 F3-F4 纤维化 58%,高于 HBV 单感染 32%(P < .0001),与 HCV 单感染 52% 相似(P = .3142)。
  • 合并感染者失代偿期肝硬化 11%,高于 HBV 单感染 2%(P = .0002)和 HCV 单感染 4%(P = .0275)。
  • 作者认为抗 HCV 治疗在合并感染与单感染中同样安全有效,应按 HCV 单感染相同规则考虑。

核心结论

  • HCV 合并感染对 HBV 患者的肝纤维化有不利影响。
  • 与 HBV 或 HCV 单感染相比,合并感染者失代偿期肝硬化增加。
  • 抗 HCV 治疗在合并感染与单感染中同样安全有效,应按 HCV 单感染相同规则考虑。

研究设计与样本

  • ANRS CO22 HEPATHER 队列研究,共纳入 20936 例患者。
  • 95 例 HBV/HCV 合并感染者(乙型肝炎表面抗原、抗-HCV 抗体及 HCV RNA 阳性)按年龄、性别及 HBV 或 HCV 诊断时间与 375 例 HBV 单感染和 380 例 HCV 单感染患者匹配。

主要发现

  • F3-F4 纤维化在合并感染者中为 58%,高于 HBV 单感染的 32%(P < .0001),与 HCV 单感染的 52% 相似(P = .3142)。
  • 失代偿期肝硬化在合并感染者中为 11%,高于 HBV 单感染的 2%(P = .0002)和 HCV 单感染的 4%(P = .0275)。
  • 既往过量饮酒在合并感染者中为 26%,高于 HBV 单感染的 12%(P = .0011),与 HCV 单感染的 32% 相似(P = .2868)。
  • 动脉性高血压在合并感染者中为 42%,高于 HBV 单感染的 26% 和 HCV 单感染的 25%(P < .003)。
  • 多因素分析证实 HBV 感染者中 F3-F4 纤维化与 HCV 感染相关(OR = 3.84,95% CI 1.99-7.43)。

临床怎么用

  • 作者认为抗 HCV 治疗在合并感染与单感染患者中同样安全有效。
  • 作者认为抗 HCV 治疗应按 HCV 单感染患者的相同规则考虑。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Hepatitis B virus (HBV)/hepatitis C virus (HCV) confection has been rarely studied in nonasian series. AIM: To compare the characteristics of HBV/HCV coinfected patients to those of HBV- or HCV-monoinfected patients in the ANRS CO22 HEPATHER cohort study. PATIENTS AND METHODS: Of the 20 936 included patients, 95 had HBV/HCV coinfection (hepatitis B surface antigen, anti-HCV antibody and HCV RNA positive) and were matched with 375 HBV- and 380 HCV-monoinfected patients on age, gender and time since HBV or HCV diagnosis. RESULTS: F3-F4 fibrosis was more frequent in coinfected patients (58%) than in HBV- (32%, P < .0001), but similar in HCV-monoinfected patients (52%, P = .3142). Decompensated cirrhosis was more frequent in coinfected patients (11%) than in HBV- (2%, P = .0002) or HCV- (4%, P = .0275) monoinfected patients. Past excessive alcohol use was more frequent in coinfected patients (26%) than in HBV (12%, P = .0011), but similar in HCV monoinfected patients (32%, P = .2868). Coinfected patients had a higher proportion with arterial hypertension (42%) than HBV- (26%) or HCV-monoinfected patients (25%) (P < .003). Multivariable analysis confirmed the association between F3-F4 fibrosis and HCV infection in HBV-infected patients (OR = 3.84, 95% CI 1.99-7.43) and the association between decompensated cirrhosis and coinfection in HBV infected (OR = 5.58, 95% CI 1.42-22.0) or HCV infected patients (OR = 3.02, 95% CI 1.22-7.44). CONCLUSIONS: HCV coinfection harmfully affects liver fibrosis in HBV patients, while decompensated cirrhosis is increased in coinfected patients compared with HBV- or HCV-monoinfected patients. HCV treatment is as safe and effective in coinfected as monoinfected patients and should be considered following the same rules as HCV monoinfected patients.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Pol S, Haour G, Fontaine H, et al. The negative impact of HBV/HCV coinfection on cirrhosis and its consequences. Aliment Pharmacol Ther. 2017. PMID: 28994127. doi:10.1111/apt.14352

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。